(Bloomberg) -- When tiny ChemoCentryx won US approval for a pill to treat a rare blood vessel disorder in 2021, executives touted it as a major advance. The next year, Amgen Inc. paid $3.7 billion to ...

An attacker broke into competitive-intelligence vendor Klue, stole OAuth tokens its customers use to connect to Salesforce and other platforms, and accessed data across multiple customer environments ...